MacArthur John W, Steele Amanda N, Goldstone Andrew B, Cohen Jeffrey E, Hiesinger William, Woo Y Joseph
Department of Cardiothoracic Surgery, Stanford University, Falk Cardiovascular Research Bldg, 2nd Floor, 300 Pasteur Drive, Stanford, CA, 94305-5407, USA.
Curr Treat Options Cardiovasc Med. 2017 Apr;19(4):30. doi: 10.1007/s11936-017-0530-x.
Over the past two decades, the field of cardiovascular medicine has seen the rapid development of multiple different modalities for the treatment of ischemic myocardial disease. Most research efforts have focused on strategies aimed at coronary revascularization, with significant technological advances made in percutaneous coronary interventions as well as coronary artery bypass graft surgery. However, recent research efforts have shifted towards ways to address the downstream effects of myocardial infarction on both cellular and molecular levels. To this end, the broad application of injectable hydrogel therapy after myocardial infarction has stimulated tremendous interest. In this article, we will review what hydrogels are, how they can be bioengineered in unique ways to optimize therapeutic potential, and how they can be used as part of a treatment strategy after myocardial infarction.
在过去的二十年里，心血管医学领域见证了用于治疗缺血性心肌病的多种不同方式的快速发展。大多数研究工作都集中在旨在冠状动脉血运重建的策略上，经皮冠状动脉介入治疗以及冠状动脉旁路移植手术都取得了重大技术进步。然而，最近的研究工作已转向在细胞和分子水平上解决心肌梗死下游效应的方法。为此，心肌梗死后可注射水凝胶疗法的广泛应用引起了极大的兴趣。在本文中，我们将回顾水凝胶是什么，如何以独特的方式对其进行生物工程改造以优化治疗潜力，以及它们如何用作心肌梗死后治疗策略的一部分。
